• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Discovery of the covalent SARS-CoV-2 Mpro inhibitors from antiviral herbs via integrating target-based high-throughput screening and c

tetano

Editor, Senior Moderator
J Med Virol


. 2023 Nov;95(11):e29208.
doi: 10.1002/jmv.29208. Discovery of the covalent SARS-CoV-2 M[SUP]pro[/SUP] inhibitors from antiviral herbs via integrating target-based high-throughput screening and chemoproteomic approaches

Ya-Ni Zhang[SUP] 1 [/SUP], Guang-Hao Zhu[SUP] 1 [/SUP], Wei Liu[SUP] 2 [/SUP], Xi-Xiang Chen[SUP] 1 [/SUP], Yuan-Yuan Xie[SUP] 3 [/SUP], Jian-Rong Xu[SUP] 3 [/SUP], Mei-Fang Jiang[SUP] 1 [/SUP], Xiao-Yu Zhuang[SUP] 1 [/SUP], Wei-Dong Zhang[SUP] 1 [/SUP], Hong-Zhuan Chen[SUP] 1 3 [/SUP], Guang-Bo Ge[SUP] 1 [/SUP]



Affiliations
Abstract

The main proteases (M[SUP]pro[/SUP] ) are highly conserved cysteine-rich proteins that can be covalently modified by numerous natural and synthetic compounds. Herein, we constructed an integrative approach to efficiently discover covalent inhibitors of M[SUP]pro[/SUP] from complex herbal matrices. This work begins with biological screening of 60 clinically used antiviral herbal medicines, among which Lonicera japonica Flos (LJF) demonstrated the strongest anti-M[SUP]pro[/SUP] effect (IC[SUB]50[/SUB] = 37.82 μg/mL). Mass spectrometry (MS)-based chemical analysis and chemoproteomic profiling revealed that LJF extract contains at least 50 constituents, of which 22 exhibited the capability to covalently modify M[SUP]pro[/SUP] . We subsequently verified the anti-M[SUP]pro[/SUP] effects of these covalent binders. Gallic acid and quercetin were found to potently inhibit severe acute respiratory syndrome coronavirus 2 M[SUP]pro[/SUP] in dose- and time- dependent manners, with the IC[SUB]50[/SUB] values below 10 µM. The inactivation kinetics, binding affinity and binding mode of gallic acid and quercetin were further characterized by fluorescence resonance energy transfer, surface plasmon resonance, and covalent docking simulations. Overall, this study established a practical approach for efficiently discovering the covalent inhibitors of M[SUP]pro[/SUP] from herbal medicines by integrating target-based high-throughput screening and MS-based assays, which would greatly facilitate the discovery of key antiviral constituents from medicinal plants.

Keywords: Lonicera japonica Flos (LJF); SARS-CoV-2 Mpro; antiviral agents; covalent inhibitors; inhibitory mechanism.

 
Back
Top Bottom